Avalo Therapeutics, Inc. AVTX
8.51 USD +1.35 (+18.85%)
At closeNov 11, 2026, 5:52 PM EST
8.40 -0.11 -1.29%
After hours · Nov 11, 5:52 PM ET
7.17 Day range 8.55
6.53 52-week range 24.27
- YTD
- -53.14%
- 1 year
- -45.10%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 44.08 +418.0% upside
Now 8.51
- Target (low)
- 30.00
- Target (mean)
- 44.08
- Target (high)
- 60.00
Ratings (0m) 14 14 buy · 0 hold · 0 sell
- Strong buy2
- Buy12
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 14
- 1 month ago 15
- 2 months ago 15
- 3 months ago 14
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.56 | -0.66 – -0.45 | -2.19 | +74.4% | 0 | 0.0% | 7 |
| Next quarter | -0.51286 | -0.70 – -0.39 | -0.37 | -38.6% | 0 | -100.0% | 7 |
| Current year | -2.72 | -3.06 – -2.18 | -5.84 | +53.4% | 0 | -100.0% | 7 |
| Next year | -2.74 | -4.10 – -1.33 | -2.72 | -0.7% | 0 | 0.0% | 9 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 2026 | Guggenheim | Maintained | Buy | Buy |
| Aug 7, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jul 6, 2026 | Leerink Partners | Initiated | — | Outperform |
| Jun 16, 2026 | BTIG | Reiterated | Buy | Buy |
| Jun 12, 2026 | B of A Securities | Initiated | — | Buy |
| May 14, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| May 14, 2026 | Wedbush | Maintained | Outperform | Outperform |
| May 14, 2026 | Mizuho | Maintained | Outperform | Outperform |
| May 14, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 11, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| May 6, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| May 6, 2026 | Wedbush | Maintained | Outperform | Outperform |
| May 6, 2026 | BTIG | Maintained | Buy | Buy |
| Apr 13, 2026 | BTIG | Reiterated | Buy | Buy |
| Apr 9, 2026 | Wolfe Research | Initiated | — | Outperform |
| Apr 6, 2026 | Citizens | Initiated | — | Market Outperform |
| Mar 25, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 24, 2026 | BTIG | Reiterated | Buy | Buy |
| Feb 2, 2026 | Guggenheim | Initiated | — | Buy |
| Jan 15, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Dec 18, 2025 | Mizuho | Initiated | — | Outperform |
| Sep 29, 2025 | BTIG | Reiterated | Buy | Buy |
| Sep 17, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 15, 2025 | Cantor Fitzgerald | Initiated | — | Overweight |
| Mar 25, 2025 | Jefferies | Initiated | — | Buy |
| Mar 25, 2025 | Stifel | Initiated | — | Buy |
| Mar 20, 2025 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Feb 28, 2025 | Piper Sandler | Initiated | — | Overweight |
| Dec 19, 2024 | BTIG | Initiated | — | Buy |
| Dec 17, 2024 | LUCID CAPITAL MARKETS | Initiated | — | Buy |